CLYM Climb Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1768446 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-16.9%
TTM EPS YoY-37.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.3%
ROA-28.3%
ROIC (approx.)-31.1%
Asset turnover—
Leverage & solvency
Liabilities / assets3.6%
Debt / equity0.00x
Current ratio26.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $11.04M | $9.71M | $9.37M | $13.74M | $9.07M | $6.58M | $17.33M | $5.96M |
| SG&A expense | $5.85M | $5.64M | $5.84M | $5.56M | $5.82M | $4.10M | $5.69M | $4.95M |
| Operating income | -$16.89M | -$15.36M | -$15.21M | -$19.30M | -$14.89M | -$10.68M | -$23.02M | -$10.91M |
| Income tax | — | — | — | — | — | — | $0 | $0 |
| Net income | -$14.57M | -$13.50M | -$13.72M | -$17.52M | -$12.89M | -$8.67M | -$20.78M | -$8.42M |
| EBITDA | -$16.70M | -$15.33M | -$15.17M | -$19.27M | -$14.86M | -$10.64M | -$23.02M | -$10.91M |
| EPS (basic) | -0.18 | -0.18 | -0.20 | — | -0.19 | -0.13 | -0.31 | — |
| EPS (diluted) | -0.18 | -0.18 | -0.20 | — | -0.19 | -0.13 | -0.31 | — |
| Weighted avg. shares (diluted) | 80.03M | 76.15M | 68.21M | — | 68.00M | 67.59M | 67.46M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $39.73M | $44.11M | $8.36M | $35.69M | $25.80M | $22.68M | $29.02M | $87.23M |
| Short-term investments | $165.69M | $139.02M | $101.21M | $65.39M | $61.10M | $62.02M | $69.04M | $63.69M |
| Current assets | $210.15M | $186.64M | $113.40M | $105.85M | $90.96M | $87.38M | $100.28M | $154.87M |
| PP&E, net | $1.33M | $695,000 | $250,000 | $288,000 | $318,000 | $314,000 | — | $199,000 |
| Total assets | $236.56M | $246.29M | $152.37M | $167.74M | $182.30M | $192.39M | $200.74M | $217.19M |
| Current liabilities | $7.91M | $5.93M | $4.07M | $6.98M | $4.95M | $6.21M | $7.04M | $4.93M |
| Total liabilities | $8.51M | $6.75M | $4.29M | $7.27M | $5.30M | $6.62M | $7.36M | $5.31M |
| Shareholders' equity | $228.05M | $239.55M | $148.09M | $160.47M | $177.00M | $185.76M | $193.38M | $211.88M |
| Shares outstanding | 57.73M | 57.44M | 47.77M | 47.77M | 68.18M | 67.76M | 67.58M | 67.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$12.00M | -$10.55M | -$14.38M | -$15.63M | -$12.14M | -$11.15M | -$15.43M | -$5.52M |
| Capital expenditure | $820,000 | — | — | $0 | $109,000 | — | — | $0 |
| Free cash flow | -$12.82M | — | — | -$15.63M | -$12.25M | — | — | -$5.52M |
| Investing cash flow | $6.40M | -$57.26M | -$12.96M | $25.54M | $15.26M | $4.79M | -$42.75M | -$53.41M |
| Financing cash flow | $1.22M | $103.70M | $5,000 | -$21,000 | $0 | $0 | $0 | $41,000 |
| Depreciation & amortization | $195,000 | $33,000 | $38,000 | $30,000 | $29,000 | $38,000 | $0 | $0 |
| Stock-based compensation | $2.04M | $1.48M | $1.60M | $1.04M | $3.98M | $1.01M | $2.02M | $1.66M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.